Yale University Cancer Center
Oncology
Dr. Daniel P. Petrylak, MD
|
|
Give Review
Daniel Petrylak practices Oncology. He attended Albert Einstein College of Medicine at Jacobi Medical Center. He has 6 awards "CMS Meaningful Use Stage 1 Certification", "America's Top Doctors", "Top Doctors: New York Metro Area", "New York Magazine: Top Doctors", "America's Top Doctors for Cancer" and "Super Doctor". Daniel P. Petrylak, MD is also a published MD. He has 71 publication published. The most recent publication is: Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-a... He is registered with Medicare and accepts Medicare payments.
Publications
- Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-a...
- Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
- Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel.
- Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castratio...
- A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate Cancer.
- Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate Cancer.
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder Cancer.
- Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate Cancer treated with sipuleucel-T.
- Challenges in treating advanced disease.
- Current state of castration-resistant prostate Cancer.
- An open-label, single-arm, phase 2 trial of the polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial Cancer.
- Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
- Prognostic model predicting metastatic castration-resistant prostate Cancer survival in men treated with second-line chemotherapy.
- Six-Month Progression-Free Survival as the Primary Endpoint to Evaluate the Activity of New Agents as Second-line Therapy for Advanced Urothelial Carcinoma.
- The utility of prostate-specific antigen in the management of advanced prostate Cancer.
- SWOG S0353: Phase II Trial of Intravesical Gemcitabine in Patients with Nonmuscle Invasive Bladder Cancer and Recurrence after 2 Prior Courses of Intravesical Bacillus...
- Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective Analysis of pooled, prospec...
- Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate Cancer.
- Suppression of Acquired Docetaxel Resistance in Prostate Cancer through Depletion of Notch- and Hedgehog-Dependent Tumor-Initiating Cells.
- Alpha particles as radiopharmaceuticals in the treatment of bone metastases: mechanism of action of radium-223 chloride (Alpharadin) and radiation protection.
- Relative Efficacy of Perioperative Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Adriamycin, and Cisplatin in the Management of Locally Advanced Urotheli...
- Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer.
- Biomarkers in the Management and Treatment of Men with Metastatic Castration-Resistant Prostate Cancer.
- New data, new paradigms for treating prostate Cancer patients--VI: novel hormonal therapy approaches.
- A phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of bacillus Calmette-Guérin refractory nonmuscle invasive bladder Cancer.
- A comparison of the outcomes of neoadjuvant and adjuvant chemotherapy for clinical T2-T4aN0-N2M0 bladder Cancer.
- Current clinical trials in castrate-resistant prostate Cancer.
- Evolving therapeutic paradigms for advanced prostate Cancer: what's needed to make optimal use of the new treatments.
- Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder Cancer refractory to standard intravesical th...
- Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate Cancer progressing after pri...
- Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate Cancer: data from Southwest Oncology Group Trials 9346 (Intergroup...
- A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate Cancer treated with intermittent androgen ablation.
- COOPERATIVE GROUP TRIALS - SOUTHWEST ONCOLOGY GROUP (SWOG) INNOVATIONS IN ADVANCED PROSTATE Cancer.
- Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the Bladder.
- Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate Cancer.
- Phase II open-label study of Oral piritrexim in patients with advanced carcinoma of the urothelium who have experienced failure with standard chemotherapy.
- Activation of targeted necrosis by a p53 peptide: a novel death pathway that circumvents apoptotic resistance.
- Clinical trials in metastatic hormone-refractory prostate Cancer: improving docetaxel therapy by targeting bone-related growth factors.
- Adjuvant weekly docetaxel for patients with high risk prostate Cancer after radical prostatectomy: a multi-institutional pilot study.
- A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate Cancer...
- New paradigms for advanced prostate Cancer.
- The case for early chemotherapy for the treatment of metastatic disease.
- Cytotoxic chemotherapy for prostate Cancer: Who and when?
- Phase I trial of intravesical docetaxel in the management of superficial bladder Cancer refractory to standard intravesical therapy.
- Management of asymptomatic rise in prostatic-specific antigen in patients with prostate Cancer.
- Evaluation of Prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.
- The treatment of hormone-refractory prostate Cancer: docetaxel and beyond.
- Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study.
- Future directions in the treatment of androgen-independent prostate Cancer.
- Chemotherapy agents and timing of chemotherapy in prostate Cancer management.
- Complications of androgen-deprivation therapy in men with prostate Cancer.
- The current role of chemotherapy in metastatic hormone-refractory prostate Cancer.
- Adjuvant chemotherapy for transitional cell carcinoma of the Bladder: paradigms for the design of clinical trials.
- Docetaxel-based chemotherapy trials in androgen-independent prostate Cancer: first demonstration of a survival benefit.
- A prospective Analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinica...
- Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate Cancer.
- Complications of androgen deprivation therapy in men with prostate Cancer.
- The "skinny" on obesity and prostate Cancer prognosis.
- Early chemohormonal therapy in prostate Cancer: preliminary data and randomized trials.
- Management of high-risk localized prostate Cancer: the integration of local and systemic therapy approaches.
- Fas-mediated apoptosis is dependent on wild-type p53 status in human Cancer cells expressing a temperature-sensitive p53 mutant alanine-143.
- A phase II trial of docetaxel and estramustine in patients with refractory metastatic breast carcinoma.
- Hormone-refractory prostate Cancer: new horizons.
- Docetaxel for the treatment of hormone-refractory prostate Cancer.
- The novel antimicrotubule agent cryptophycin 52 (LY355703) induces apoptosis via multiple pathways in human prostate Cancer cells.
- Chemotherapy for androgen-independent prostate Cancer.
- Editorial: the coming revolution in the treatment of prostate Cancer patients.
- Salvage therapy for platinum-refractory urothelial Cancer: designing new clinical trials.
- Could PD-L1 prove to be an effective therapeutic target for bladder Cancer?
Schools
Case Western Reserve University School of Medicine
Jacobi Hospital
Bronx Municipal Hospital Center
Mem Sloan Kettering Cancer Center
Meml Sloan Kettering Center
Columbia U
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Bladder Cancer
- Cancer
- View All
Doctors Specialties
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Amalgamated Clothing & Textile Workers Union WC
- Amerigroup (Wellpoint)
- Blue Card PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access
- Commercial Insurance Company
- Emblem Health
- Empire Blue Cross Blue Shield HMO
- Fidelis Care HMO
- Golden Rule
- Group Health Cooperative
- Medicare Advantage PFFS
- HealthFirst
- Locals (any local)
- Mail Handlers Benefit Plan (MHBP)
- Medicaid
- Medicare MCR
- MVP Health Care PPO
- Neighborhood Health Plan
- Freedom Plan
- POMCO Group
- Principal Life
- TriCare for Life
- Choice Plus POS
- Options PPO
- Oxford Liberty
- United Healthcare
Awards
- CMS Meaningful Use Stage 1 Certification
- America's Top Doctors
- Top Doctors: New York Metro Area
- New York Magazine: Top Doctors
- America's Top Doctors for Cancer
- Super Doctor
Education
-
Memorial Sloan-Kettering Cancer Center -
Albert Einstein College of Medicine at Jacobi Medical Center -
Case Western Reserve University School of Medicine
Hospital
-
Yale-New Haven Hospital -
Greenwich Hospital
Drug Facts
| NPI NUMBER | 1659387306 | |
| NPPES Provider LastName | PETRYLAK | |
| NPPES Provider FirstName | DANIEL | |
| NPPES Provider ZIPCode | 065101110 | |
| NPPES Provider State | CT | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 559.0 | |
| Distinct Opioid Count | 3.0 | |
| Opioid Claim Count | 47.0 | |
| Percent Opioid Claims | 8.41 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1659387306 |
| Last Name Of The Provider | PETRYLAK |
| First Name Of The Provider | DANIEL |
| View All |
Similar Doctors
|
|
Dr. Francine M. Foss, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stacey M. Stein, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Harriet M. Kluger, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Roy S. Herbst, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Warren D. Shlomchik, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Diamando Psyrri, MD
This Doctor is OpenDoctor Recommended.
|